The estimated Net Worth of John M. Gay is at least $414 Thousand dollars as of 6 June 2023. Mr Gay owns over 65,000 units of Novan Inc stock worth over $6,075 and over the last 6 years he sold NOVN stock worth over $0. In addition, he makes $408,031 as CFO & Corp. Sec. at Novan Inc.
Mr has made over 3 trades of the Novan Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 65,000 units of NOVN stock worth $5,850 on 6 June 2023.
The largest trade he's ever made was exercising 65,000 units of Novan Inc stock on 6 June 2023 worth over $5,850. On average, Mr trades about 10,113 units every 185 days since 2019. As of 6 June 2023 he still owns at least 67,500 units of Novan Inc stock.
You can see the complete history of Mr Gay stock trades at the bottom of the page.
John M. Gay is the CFO & Corp. Sec. at Novan Inc.
As the CFO & Corp. Sec. of Novan Inc, the total compensation of Mr Gay at Novan Inc is $408,031. There are 3 executives at Novan Inc getting paid more, with Paula Brown Stafford having the highest compensation of $897,864.
Mr Gay is 43, he's been the CFO & Corp. Sec. of Novan Inc since . There are 13 older and no younger executives at Novan Inc. The oldest executive at Novan Inc is Robert Ingram, 77, who is the Independent Director.
John's mailing address filed with the SEC is C/O NOVAN, INC., 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM, NC, 27703.
Over the last 8 years, insiders at Novan Inc have traded over $72,487 worth of Novan Inc stock and bought 1,476,993 units worth $9,839,419 . The most active insiders traders include John W Palmour, Robert J Keegan, and Life Sciences Holdings Ltd .... On average, Novan Inc executives and independent directors trade stock every 70 days with the average trade being worth of $4,566. The most recent stock trade was executed by Machelle Sanders on 27 June 2023, trading 11,553 units of NOVN stock currently worth $4,737.
novan, inc. is a clinical-stage biotechnology company focused on leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. we believe that our ability to conveniently deploy nitric oxide in a solid form, on demand and in localized formulations allows us the potential to significantly improve patient outcomes in a variety of diseases.
Novan Inc executives and other stock owners filed with the SEC include: